Avalo Therapeutics (AVTX) CMO exercises options, sells 4,654 pre-planned shares

Rhea-AI Filing Summary

Avalo Therapeutics Chief Medical Officer Mittie Doyle reported an exercise-and-sell transaction in Avalo Therapeutics, Inc. common stock. On June 30, 2026, Doyle sold 4,654 shares in an open-market sale at $20.00 per share, while also exercising options to acquire a total of 4,654 shares of common stock at strike prices of $8.04 and $12.65 per share. The options exercised relate to grants that vest over four years, and all transactions were carried out under a Rule 10b5-1 trading plan adopted on November 13, 2025, indicating the trades were pre‑scheduled rather than discretionary market timing.

Insider Trade Summary 10b5-1

Net Seller: 4,654 shares ($93,080)

Net Sell 5 txns

Insider Doyle Mittie

Role Chief Medical Officer

Sold 4,654 shs ($93K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,875	$0.00	--
Exercise	Stock Option (Right to Buy)	1,779	$0.00	--
Exercise	Common Stock	2,875	$12.65	$36K
Exercise	Common Stock	1,779	$8.04	$14K
Sale	Common Stock	4,654	$20.00	$93K

Holdings After Transaction: Stock Option (Right to Buy) — 125,750 shares (Direct, null); Common Stock — 54,651 shares (Direct, null)

Footnotes (1)

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Shares sold: 4,654 shares Sale price: $20.00/share Options exercised (8.04): 1,779 shares at $8.04 +4 more

7 metrics

Shares sold 4,654 shares Open-market sale of common stock at $20.00 per share on June 30, 2026

Sale price $20.00/share Price for 4,654 common shares sold in open-market transaction

Options exercised (8.04) 1,779 shares at $8.04 Common stock acquired via option exercise on June 30, 2026

Options exercised (12.65) 2,875 shares at $12.65 Common stock acquired via option exercise on June 30, 2026

Rule 10b5-1 plan adoption November 13, 2025 Date the trading plan governing these transactions was adopted

Option expiration (8.04 strike) January 28, 2035 Expiration date for stock option with $8.04 exercise price

Option expiration (12.65 strike) July 15, 2034 Expiration date for stock option with $12.65 exercise price

Key Terms

Rule 10b5-1 trading plan, stock option, Exercise or conversion of derivative security, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

stock option financial

"The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

vesting financial

"the remainder will vest in equal monthly installments over the following three (3) years"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:06 PM Accepted by SEC EDGAR 07/02/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doyle Mittie

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2026		M(1)		2,875	A	$12.65	54,651	D
Common Stock	06/30/2026		M(1)		1,779	A	$8.04	56,430	D
Common Stock	06/30/2026		S(1)		4,654	D	$20	51,776	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.65	06/30/2026		M(1)			2,875	(2)	07/15/2034	Common Stock	2,875	$0	125,750	D
Stock Option (Right to Buy)	$8.04	06/30/2026		M(1)			1,779	(3)	01/28/2035	Common Stock	1,779	$0	115,092	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

2. The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

3. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Avalo Therapeutics (AVTX) insider Mittie Doyle report in this Form 4?

Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, reported an exercise-and-sell transaction. She exercised stock options for 4,654 common shares and sold 4,654 shares in an open-market trade, aligning the sale size with the options exercised on the same date.

How many Avalo Therapeutics (AVTX) shares did Mittie Doyle sell and at what price?

Mittie Doyle sold 4,654 shares of Avalo Therapeutics common stock at $20.00 per share. This open-market sale was disclosed as a single non-derivative transaction and formed part of a broader exercise-and-sell pattern executed on June 30, 2026.

What stock options did Mittie Doyle exercise in Avalo Therapeutics (AVTX)?

She exercised options covering 1,779 shares at an $8.04 strike price and 2,875 shares at a $12.65 strike price. These options convert into common stock and are tied to multi-year vesting schedules described in the accompanying footnotes.

Were Mittie Doyle’s Avalo Therapeutics (AVTX) trades pre-planned under Rule 10b5-1?

Yes. The Form 4 states that all reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Such plans pre-schedule trades, reducing the significance of short-term market timing considerations for these sales.

What are the expiration dates of the Avalo Therapeutics (AVTX) options exercised by Mittie Doyle?

The options exercised include grants expiring on July 15, 2034 and January 28, 2035. Each option grant vests 25% on its initial vesting date, with the remaining portion vesting in equal monthly installments over the following three years, contingent on continued service.

How do the vesting terms affect Mittie Doyle’s Avalo Therapeutics (AVTX) option grants?

Each option grant vests 25% on a specified initial date, then vests monthly over three years. Continued service with Avalo Therapeutics is required for each vesting installment, meaning future option availability depends on ongoing employment at those vesting dates.